Eli Lilly and Company recently announced that Jardiance slowed kidney function decline in adults with heart failure with left ventricular ejection fraction (LVEF) over 40 percent regardless of chronic...
Johnson & Johnson recently entered into an agreement with the US government and Gavi, the Vaccine Alliance, to allow access to its single-shot COVID-19 vaccine through the COVAX Humanitarian...
GSK recently announced that its drug, daprodustat, was safe and effective in patients with anemia due to chronic kidney disease (CKD).
The Phase 3 ASCENT trial studied the hypoxia-inducible...
Gilead and Merck recently announced the start of a Phase 2 clinical study evaluating a combination HIV treatment regimen in adults living with the disease.
The open-label study will evaluate the...
Merck and Ridgeback Biotherapeutics recently announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) authorized their COVID-19 treatment for adults.
The UK’s...
Abbott recently launched a new initiative to increase clinical trial diversity in medical research through training, education, and improved clinical research infrastructure throughout the...
Pfizer recently announced that its COVID-19 treatment, PAXLOVID, reduced hospitalization and death in high-risk adults with coronavirus by 89 percent compared to placebo.
In the Phase 2/3...
The CDC Advisory Committee on Immunization Practices (ACIP) recently recommended Pfizer and BioNTech’s pediatric COVID-19 vaccine for children five to 11 years of age.
The organization now...
Moderna recently dosed the first participant in the Phase 3 pivotal registration study of its cytomegalovirus (CMV) mRNA vaccine candidate, mRNA-1647.
The CMVictory study will evaluate the safety and...
Daiichi Sankyo and AstraZeneca recently entered into a second clinical trial collaboration and supply agreement with Merck to evaluate an antibody-drug conjugate with Keytruda in patients with...
Eli Lilly and Company recently announced that tirzepatide elicited superior A1C and body weight reductions from baseline in adults with type 2 diabetes with increased cardiovascular risk.
Data...
Bristol Myers Squibb recently announced interim results from a Phase 3 open-label extension trial, which showed the long-term efficacy and safety profile of Zeposia in patients with relapsing forms of...
FDA recently approved Eli Lilly and Company’s Verzenio to treat adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), early breast...
Moderna recently announced that two doses of its COVID-19 vaccine showed a robust neutralizing antibody response in children six to under 12 years of age.
The Phase 2/3 KidCOVE randomized...
Pfizer and BioNTech recently announced that their COVID-19 vaccine booster was 95.6 percent effective in individuals compared to placebo.
The randomized, controlled Phase 3 trial...
FDA recently approved Rethymic to treat pediatric patients with rare disease congenital athymia.
Congenital athymia is a rare immune disorder in which a child is born without a thymus. The...
FDA recently awarded 11 new clinical trial research grants, totaling $25 million over the next four years to support the development of medical products for patients with rare diseases.
The...
FDA recently granted Roche’s anti-amyloid beta antibody, gantenerumab, breakthrough therapy designation to treat individuals living with Alzheimer’s disease.
The agency based its...
AstraZeneca recently announced that its COVID-19 antibody, AZD7442, reduced severe COVID-19 or death compared to placebo in non-hospitalized patients with mild-to-moderate symptomatic...
GSK recently welcomed the World Health Organization’s (WHO) recommendation for the broader development of GSK’s RTS, S malaria vaccine to reduce childhood illness and deaths from malaria in...
